Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.35 |
| ▸ | RXRG | P48443 | 11/20 | 0.34 |
| ▸ | RXRB | P28702 | 11/20 | 0.34 |
| ▸ | RARB | P10826 | 5/20 | 0.34 |
| ▸ | RARG | P13631 | 5/20 | 0.34 |
| ▸ | RARA | P10276 | 5/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197626 | 0.77 | RXRA (0.36) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL10515346 | 0.75 | RXRA (0.39) | RXRARXRGRXRB | |
| SCHEMBL5491284 | 0.74 | RXRA (0.35) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL5486085 | 0.74 | RXRA (0.31) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL4446990 | 0.74 | RXRA (0.36) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL8560479 | 0.74 | RARA (0.34) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL11599145 | 0.72 | RXRA (0.42) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL5492492 | 0.72 | RXRA (0.33) | RXRARARBRARGRARA | |
| SCHEMBL7622765 | 0.71 | RXRA (0.48) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL7583942 | 0.67 | RARG (0.32) | RXRARARBRARGRARACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | claimed |
| EP-1461028-A4 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | UNIV CALIFORNIA (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004098506-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1461028-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | The Regent of the University of California (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | claimed |
| EP-1390337-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | Givaudan SA (CH) | 2004-02-25 | — | — | EP | claimed |
| US-20030229062-A1 | Treatments for age-related macular degeneration (AMD) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-12-11 | — | — | US | claimed |
| US-20030162758-A1 | Treatment for age-related macular degeneration (AMD) | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-08-28 | — | — | US | claimed |
| WO-2003049685-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-06-19 | — | — | WO | claimed |
| WO-2002096850-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | claimed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | claimed |
| EP-1214305-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| JP-2002505318-A | — | — | 2002-02-19 | — | — | JP | claimed |
| US-6218426-B1 | FOR THERAPY OF MAMMALIAN REPRODUCTIVE DISORDERS AND STEROID HORMONE-DEPENDENT TUMORS AS WELL AS FOR REGULATING FERTILITY, WHERE SUPPRESSION OF GONADOTROPIN RELEASE IS INDICATED | AGOURON PHARMACEUTICALS, INC. | 2001-04-17 | — | — | US | claimed |
| WO-2001016123-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1068178-A1 | NON-PEPTIDE GnRH AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999044987-A1 | NON-PEPTIDE GnRH AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171516-A1 | Precursors for ketones and aldehydes | PDK3, PDK4, AKR1C4 | RXRA 2042/4885RXRG 2058/4885RXRB 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.